SAGE Therapeutics Q2 revenue rises sequentially

Sage Therapeutics

30/07/2025 21:18

Overview

SAGE Therapeutics Q2 collaboration revenue from ZURZUVAE rises 68% from Q1 2025

Company's acquisition by Supernus Pharmaceuticals expected to close in Q3 2025

Net loss for Q2 2025 was $49.7 mln, cash position at $366 mln

Outlook

Company anticipates investments will help topline revenue growth in 2025

SAGE-319 Phase 1 study data expected by late 2025

Company to update on SAGE-324 indications by mid-2025

Supernus acquisition expected to close in Q3 2025

Result Drivers

ZURZUVAE REVENUE - Collaboration revenue from ZURZUVAE increased 68% from Q1 2025, driven by commercialization efforts

PRESCRIPTION GROWTH - Over 4,000 prescriptions shipped in Q2 2025, a 36% increase from Q1 2025

OBGYN PRESCRIBERS - OBGYNs accounted for 80% of all prescriptions in Q2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$23.21 mln
Q2 Net Income
-$49.65 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 14 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.50, about 2.4% below its July 29 closing price of $8.70

Press Release: ID:nBw127GQHa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)